3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
NIH
3
OTHER
1
NETWORK
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Colorectal Neoplasms
114
Neoplasms
37
Neoplasm Metastasis
23
Stomach Neoplasms
22
Pancreatic Neoplasms
18
Colonic Neoplasms
15
Rectal Neoplasms
13
Esophageal Squamous Cell Carcinoma
12
Sarcoma
10
Esophageal Neoplasms
10
Carcinoma, Non-Small-Cell Lung
10
Small Cell Lung Carcinoma
8
Sarcoma, Ewing
8
Breast Neoplasms
8
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Glioblastoma
7
Ovarian Neoplasms
6
Gastrointestinal Neoplasms
6
Uterine Cervical Neoplasms
5
Solid Tumors
5
Recurrence
5
Neuroblastoma
5
Intestinal Neoplasms
5
Digestive System Neoplasms
5
Cholangiocarcinoma
5
Advanced Solid Tumor
5
Rhabdomyosarcoma
4
Gastrointestinal Diseases
4
Endometrial Neoplasms
4
Digestive System Diseases
4
Interventions
robatumumab
1
pegfilgrastim
1
omburtamab I-131
1
lenvatinib
1
exatecan
1
cixutumumab
1
amino-acid, glucose, and electrolyte solution
1
Temozolomide
1
Irinotecan
1
Fentanyl
1
FANG vaccine
1
Everolimus
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neuroectodermal Tumors, Primitive, Peripheral
×
Irinotecan
×
Clear all
NCT03495921
2023-04-26
VITA
Gradalis, Inc.
Phase 3
Terminated
32 enrolled
13 charts